M&A and equity raisings
6,065 deals since January 2025, with sources and adviser credits where available · as at 20 Nov 2026 · Venture rounds
US deals dated after 30 September 2026 are still being collected.
124 deals · US$156bndisclosed · Biotech · Clear
Columns
| Date | Target | Vendor | Acquirer | Type | Status | Value US$m | Sector | Advisers |
|---|---|---|---|---|---|---|---|---|
| Jun 2026 | Vega Therapeutics | Star Therapeutics | Incyte | Acquisition | Completed | 1,250.0 | Biotech+2 | Lazard (buy-side)Evercore (sell-side)Morgan Stanley (sell-side)Fenwick & West (sell-side)Goodwin (buy-side) |
| Jun 2026 | Standard BioTools | – | – | Merger | Pending | 460.0 | Biotech+2 | Wedbush Securities (sell-side)Fenwick & West (sell-side)Centerview Partners (buy-side)Freshfields (buy-side)Richards, Layton & Finger (buy-side)UBS (buy-side) |
| Jun 2026 | Genesis Molecular AI | – | Incyte | Stake | Announced | 40.0 | AI+1 | Goodwin (buy-side) |
| Jun 2026 | Avenzo Therapeutics | – | Rallybio | Acquisition | Pending | – | Biotech+2 | Leerink Partners (sell-side)Cooley (sell-side)Evercore (buy-side)Citizens JMP (buy-side)Ropes & Gray (buy-side) |
| Jun 2026 | Sevasemten and Edgewise muscular dystrophy business | Edgewise Therapeutics | Servier | Asset sale | Completed | 1,550.0 | Biotech+2 | LazardCenterview Partners (sell-side)Wilson Sonsini Goodrich & Rosati (sell-side) |
| May 2026 | Curevo Vaccine | – | Eli Lilly | Acquisition | Pending | 1,500.0 | Biotech+1 | Cooley (sell-side)Centerview Partners (sell-side) |
| May 2026 | Vaccine Company | – | Lilly | Acquisition | Announced | 1,550.0 | Biotech+1 | Lazard (sell-side)Cooley (sell-side) |
| May 2026 | Engage Bio | – | Eli Lilly | Acquisition | Announced | 202.0 | Biotech+1 | Cooley (sell-side) |
| May 2026 | Mentari Therapeutics | – | InMed Pharmaceuticals | Acquisition | Announced | – | Biotech+1 | Wedbush Securities (sell-side)Gibson Dunn (sell-side)Lucid Capital Markets (buy-side)Norton Rose Fulbright (buy-side) |
| May 2026 | Orphai Therapeutics | – | Quince Therapeutics | Acquisition | Completed | – | Biotech+2 | Cooley (sell-side)LifeSci Capital (buy-side)Dorsey & Whitney (buy-side)Oppenheimer & Co. (buy-side)Gibson Dunn (buy-side) |
| May 2026 | Anagram Therapeutics | – | – | Stake | Announced | – | Biotech+2 | Goodwin (sell-side) |
| May 2026 | CDMO and Cell Solutions businesses of Charles River Laboratories | Charles River Laboratories International | GI Partners | Asset sale | Completed | – | Pharma Services+2 | Moelis & Company (buy-side)Ropes & Gray (buy-side) |
| May 2026 | Perfuse Therapeutics | – | Bayer | Acquisition | Announced | 300.0 | Biotech+2 | Goodwin (sell-side) |
| May 2026 | Candid Therapeutics | – | UCB | Acquisition | Announced | 2,200.0 | Biotech+1 | LazardCooley (sell-side) |
| May 2026 | LimmaTech Biologics AG | – | Eli Lilly and Company | Acquisition | Pending | 780.0 | Biotech | Goodwin (sell-side)Kirkland & Ellis (buy-side) |
| May 2026 | Replay | – | LEO Pharma | Acquisition | Announced | 50.0 | Biotech+2 | Latham & Watkins (buy-side) |
| Apr 2026 | KalVista Pharmaceuticals | – | Chiesi Group | Acquisition | Completed | 1,900.0 | Pharma+2 | Centerview Partners (sell-side)Kirkland & Ellis (sell-side)Fenwick & West (sell-side)Jefferies (sell-side)Lazard (buy-side)Ropes & Gray (buy-side) |
| Apr 2026 | Shionogi-Apnimed Sleep Science | Apnimed | Shionogi & Co. | Acquisition | Announced | 100.0 | Pharma+1 | Goodwin (sell-side) |
| Apr 2026 | Emalex Biosciences | – | Teva Pharmaceuticals | Acquisition | Announced | 700.0 | Pharma+1 | Centerview Partners (sell-side)Bradley Arant Boult Cummings (sell-side)Evercore (buy-side)Faegre Drinker Biddle & Reath (buy-side) |
| Apr 2026 | Ajax Therapeutics | – | Eli Lilly and Company | Acquisition | Announced | 2,300.0 | Biotech+2 | Cooley (sell-side)Kirkland & Ellis (sell-side)Ropes & Gray (buy-side) |
| Apr 2026 | XOMA Royalty | – | Ligand Pharmaceuticals | Acquisition | Completed | 739.0 | Specialty finance and leasing+2 | Leerink Partners (sell-side)H.C. Wainwright & Co. (sell-side)Gibson Dunn (sell-side)Stifel (buy-side)Citi (buy-side)Paul Hastings (buy-side)Collected Strategies (buy-side) |
| Apr 2026 | Kashiv BioSciences | – | Amneal Pharmaceuticals | Acquisition | Completed | 375.0 | Biotech+2 | J.P. Morgan (sell-side)Holland & Knight (sell-side)Goldman Sachs (buy-side)Richards, Layton & Finger (buy-side)Simpson Thacher & Bartlett (buy-side)Boston Consulting Group (buy-side) |
| Apr 2026 | Kelonia Therapeutics | – | Eli Lilly and Company | Acquisition | Announced | 7,000.0 | Biotech+2 | Goodwin (sell-side)Jefferies (sell-side)Kirkland & Ellis (buy-side) |
| Apr 2026 | Neurona Therapeutics | – | UCB | Acquisition | Announced | 650.0 | Biotech+2 | Centerview Partners (sell-side)Wilson Sonsini Goodrich & Rosati (sell-side)BofA Securities (buy-side)Covington & Burling (buy-side) |
| Apr 2026 | CrossBridge Bio | – | Eli Lilly and Company | Acquisition | Announced | 300.0 | Biotech+2 | Cooley (sell-side) |
| Apr 2026 | Obsidian Therapeutics | – | Galera Therapeutics | Merger | Completed | 413.5 | Biotech+2 | Goodwin (sell-side)Sidley Austin (buy-side)Leerink Partners (sell-side)Lucid Capital Markets (buy-side) |
| Apr 2026 | Tubulis | EQT Life Sciences (LSP 7 fund) | Gilead Sciences | Acquisition | Announced | 3,150.0 | Biotech+2 | Goodwin (sell-side)J.P. Morgan (sell-side)CMS (sell-side)Centerview Partners (buy-side)Allen & Company (buy-side)Covington & Burling (buy-side)Arnold & Porter (buy-side)Venable (buy-side) |
| Apr 2026 | Soleno Therapeutics | – | Neurocrine Biosciences | Acquisition | Completed | 2,900.0 | Biotech+2 | Centerview Partners (sell-side)Guggenheim Securities (sell-side)Wilson Sonsini Goodrich & Rosati (sell-side)Goodwin (sell-side)Goldman Sachs (buy-side)Cooley (buy-side) |
| Apr 2026 | Exclusive global rights to TAK-063 (balipodect) | Takeda Pharmaceutical Co. | Axsome Therapeutics | Asset sale | Completed | – | Pharma+1 | Sidley Austin (buy-side) |
| Apr 2026 | Modeyso commercial sales royalties | Former Oncoceutics Inc. securityholders | HealthCare Royalty | Asset sale | Announced | – | Specialty finance and leasing+3 | Latham & Watkins (sell-side) |
| Mar 2026 | Apellis Pharmaceuticals | – | Biogen | Acquisition | Announced | 5,600.0 | Biotech+2 | Lazard (buy-side)Evercore (sell-side)Wachtell, Lipton, Rosen & Katz (sell-side)WilmerHale (sell-side)Cravath, Swaine & Moore (buy-side) |
| Mar 2026 | Centessa Pharmaceuticals | – | Eli Lilly and Company | Scheme | Pending | 6,300.0 | Biotech+1 | Centerview Partners (sell-side)Jefferies (sell-side)Goodwin (sell-side)Morgan Stanley (buy-side)Kirkland & Ellis (buy-side) |
| Mar 2026 | Kezar Life Sciences | – | Aurinia Pharmaceuticals | Acquisition | Announced | 51.5 | Biotech+1 | TD Securities (sell-side)Cooley (sell-side) |
| Mar 2026 | AnaptysBio outstanding common stock | – | AnaptysBio | Buy-back | Announced | 100.0 | Biotech+1 | Piper Sandler (buy-side) |
| Mar 2026 | Eos SENOLYTIX | – | Pulmatrix | Merger | Announced | – | Biotech+1 | Palladium Capital Group (buy-side)Evolution Venture Partners (sell-side)Wilk Auslander (sell-side)Gemini Valuation Services (buy-side)Haynes Boone (buy-side) |
| Mar 2026 | Ouro Medicines | – | Gilead | Acquisition | Announced | 1,675.0 | Biotech+1 | Paul, WeissGoodwin (sell-side)Centerview Partners (buy-side) |
| Mar 2026 | Terns Pharmaceuticals | – | Merck & Co. | Acquisition | Announced | 6,700.0 | Biotech+2 | Centerview Partners (sell-side)Freshfields (sell-side)Jefferies (sell-side)Covington & Burling (buy-side)Gibson Dunn (buy-side) |
| Mar 2026 | Pikavation | Synnovation | Novartis | Acquisition | Announced | 2,000.0 | Biotech+2 | Goodwin (sell-side)Centerview Partners (sell-side) |
| Mar 2026 | Lisata Therapeutics | – | Kuva Labs | Acquisition | Pending | – | Biotech+2 | Mintz (sell-side)H.C. Wainwright & Co. (sell-side)Goodwin (buy-side)Campaign Management (buy-side) |
| Mar 2026 | Day One Biopharmaceuticals | – | Servier | Acquisition | Pending | 2,500.0 | Biotech+2 | Centerview Partners (sell-side)Fenwick & West (sell-side)Goldman Sachs (buy-side)Baker McKenzie (buy-side)Innisfree M&A (buy-side) |
| Mar 2026 | Unleash-owned rights to UIO-524, UIO-525 and UIO-526 | Unleash Immuno Oncolytics | TransCode Therapeutics | Asset sale | Pending | – | Biotech+2 | Tungsten Advisors |
| Mar 2026 | Cullgen | – | Gyre Therapeutics | Acquisition | Pending | 300.0 | Biotech+1 | Mintz (sell-side)Moelis & Company (buy-side)Gibson Dunn (buy-side) |
| Mar 2026 | Candid Therapeutics | – | Rallybio | Acquisition | Pending | – | Biotech+1 | Wedbush Securities (sell-side)Cooley (sell-side)Evercore (buy-side)Citizens JMP (buy-side)Ropes & Gray (buy-side) |
| Mar 2026 | Transcend Therapeutics | – | Otsuka | Acquisition | Announced | 700.0 | Biotech+2 | Kirkland & Ellis (sell-side)Goodwin (sell-side)Centerview Partners (sell-side)Skadden, Arps, Slate, Meagher & Flom (buy-side) |
| Feb 2026 | Precision NeuroMed | – | Brainlab SE | Stake | Completed | – | Biotech+2 | Sidley Austin (sell-side) |
| Feb 2026 | AiCuris Anti-infective Cures AG | – | Veloxis Pharmaceuticals | Acquisition | Announced | 913.0 | Pharma+1 | Gibson Dunn (sell-side)Freshfields (buy-side) |
| Feb 2026 | 35Pharma | – | GSK | Acquisition | Announced | 950.0 | Biotech+1 | Cooley (sell-side)Centerview Partners (sell-side)Paul, Weiss (buy-side) |
| Feb 2026 | Arcellx | – | Gilead Sciences | Acquisition | Announced | 7,800.0 | Biotech+2 | Centerview Partners (sell-side)Wilson Sonsini Goodrich & Rosati (sell-side)BofA Securities (buy-side)Morgan Stanley (buy-side)Ropes & Gray (buy-side)Innisfree M&A (buy-side) |
| Feb 2026 | Faeth Therapeutics | – | Sensei Biotherapeutics | Acquisition | Completed | – | Biotech+2 | Cooley (sell-side)Lucid Capital Markets (buy-side)Sidley Austin (buy-side) |
| Feb 2026 | Avadel Pharmaceuticals | – | Alkermes | Scheme | Completed | – | Pharma+1 | Goldman Sachs (sell-side)Morgan Stanley (sell-side)J.P. Morgan (buy-side) |
Deals come from stock exchange announcements and filings, takeover and scheme documents, prospectuses, the advisers' own deal announcements and the press. How the data is built All countries counts every deal, wherever it is, including deals whose geography is not known.Country pages cover Australia, New Zealand and the United States. The United Kingdom, Canada, Singapore, China and India are planned.